differ mortal patient captopril enalapril xamoterol sever heart failur studi double-blind placebo-control multin trial xamoterol sever heart failur patient captopril enalapril end follow-up period cumul probabl surviv patient coronari arteri diseas cardiomyopathi captopril group enalapril group excess mortal captopril group index sever heart failur baselin exercis durat function class cardiothorac ratio eject fraction dose diuret drug excess mortal subset patient countri examin regimen insuffici daili dosag captopril inadequ schedul administr respons differ degre angiotensin-convert enzym inhibit enalapril captopril group henc differ mortal import futur clinic trial complet circadian angiotensin-convert enzym inhibit necessari full benefit therapi heart failur 